Five-year survival outcomes in patients with a FLT3-TKD mutation, by NPM1 mutation status and treatment
| . | NPM1mut (n = 79) . | NPM1WT (n = 55) . | ||||
|---|---|---|---|---|---|---|
| . | Placebo . | Midostaurin . | HR (95% CI) . | Placebo . | Midostaurin . | HR (95% CI) . |
| OS | ||||||
| n | 34 | 45 | 30 | 25 | ||
| Estimates at 5 y (95% CI), % | 68.9 (54.5-87.0) | 70.5 (58.2-85.3) | 0.94 (0.41-2.15) | 41.4 (26.8-63.8) | 51.3 (34.9-75.6) | 0.70 (0.34-1.46) |
| EFS | ||||||
| n | 34 | 45 | 30 | 25 | ||
| Estimates at 5 y (95% CI), % | 39.7 (26.0-60.7) | 55.0 (42.1-71.8) | 0.63 (0.34-1.18) | 25.7 (13.8-47.8) | 22.4 (10.4-48.2) | 1.04 (0.57-1.92) |
| DFS | ||||||
| n | 18 | 34 | 18 | 11 | ||
| Estimates at 5 y (95% CI), % | 65.3 (48.5-88.0) | 71.9 (59.2-87.5) | 0.81 (0.32-2.01) | 46.4 (29.1-74.2) | 54.3 (35.2-83.9) | 0.64 (0.26-1.57) |
| CIR | ||||||
| n | 18 | 34 | 18 | 11 | ||
| Estimates at 5 y (95% CI), % | 26.1 (24.4-27.9) | 17.9 (17.2-18.7) | 0.67 (0.23-1.94) | 43.7 (41.1-46.2) | 45.7 (42.6-48.8) | 0.93 (0.37-2.34) |
| . | NPM1mut (n = 79) . | NPM1WT (n = 55) . | ||||
|---|---|---|---|---|---|---|
| . | Placebo . | Midostaurin . | HR (95% CI) . | Placebo . | Midostaurin . | HR (95% CI) . |
| OS | ||||||
| n | 34 | 45 | 30 | 25 | ||
| Estimates at 5 y (95% CI), % | 68.9 (54.5-87.0) | 70.5 (58.2-85.3) | 0.94 (0.41-2.15) | 41.4 (26.8-63.8) | 51.3 (34.9-75.6) | 0.70 (0.34-1.46) |
| EFS | ||||||
| n | 34 | 45 | 30 | 25 | ||
| Estimates at 5 y (95% CI), % | 39.7 (26.0-60.7) | 55.0 (42.1-71.8) | 0.63 (0.34-1.18) | 25.7 (13.8-47.8) | 22.4 (10.4-48.2) | 1.04 (0.57-1.92) |
| DFS | ||||||
| n | 18 | 34 | 18 | 11 | ||
| Estimates at 5 y (95% CI), % | 65.3 (48.5-88.0) | 71.9 (59.2-87.5) | 0.81 (0.32-2.01) | 46.4 (29.1-74.2) | 54.3 (35.2-83.9) | 0.64 (0.26-1.57) |
| CIR | ||||||
| n | 18 | 34 | 18 | 11 | ||
| Estimates at 5 y (95% CI), % | 26.1 (24.4-27.9) | 17.9 (17.2-18.7) | 0.67 (0.23-1.94) | 43.7 (41.1-46.2) | 45.7 (42.6-48.8) | 0.93 (0.37-2.34) |
Estimated Kaplan-Meier rates at 5 years (with 95% CI) and corresponding HR. This analysis was not censored at allogeneic hematopoietic cell transplant. HR <1 indicates a benefit with midostaurin.